Filing Flows › Companies › Madrigal Pharmaceuticals › Timeline
Madrigal Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−18.2% to $399.63
Madrigal Pharmaceuticals (MDGL) stock fell 18% over the last 252 sessions, to $399.63. On the way it reported 0 quarters, its insiders filed 5 open-market trades and 6 Form 144 notices of planned sales, and the company filed 5 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 6, 2026 | Form 144 | Form 144: Shannon Kelley plans to sell $431K | −0.1% (−0.4% vs SPY) | — | — |
| Nov 6, 2026 | Insider buy | Baker Bros. Advisors LP bought $23.1M | −0.1% (−0.4% vs SPY) | — | — |
| Nov 4, 2026 | Insider buy | Baker Bros. Advisors LP bought $2.1M | +1.0% (−0.6% vs SPY) | — | — |
| Sep 28, 2026 | Form 144 | Form 144: Paul Friedman plans to sell $25.8M | +0.1% (+0.8% vs SPY) | −3.4% (−3.2% vs SPY) | −16.5% (−15.8% vs SPY) |
| Sep 11, 2026 | Form 144 | Form 144: William Sibold plans to sell $2.8M | +0.3% (−0.6% vs SPY) | +0.3% (−0.4% vs SPY) | −12.2% (−15.2% vs SPY) |
| Sep 9, 2026 | Form 144 | Form 144: William John Sibold plans to sell $3.4M | +2.3% (+2.8% vs SPY) | −2.1% (−0.9% vs SPY) | −9.1% (−10.8% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Shannon Kelley plans to sell $337K | +3.4% (+3.8% vs SPY) | +1.8% (+3.2% vs SPY) | +3.1% (+5.5% vs SPY) |
| Aug 17, 2026 | Insider sale | Kelley Shannon T sold $342K | +3.4% (+3.8% vs SPY) | +1.8% (+3.2% vs SPY) | +3.1% (+5.5% vs SPY) |
| Aug 12, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.2% (−0.1% vs SPY) | −2.1% (−1.7% vs SPY) | −0.4% (+1.3% vs SPY) |
| Jul 20, 2026 | Form 144 | Form 144: William Sibold plans to sell $1.4M | −3.3% (−3.1% vs SPY) | −1.7% (−1.1% vs SPY) | −5.3% (−9.2% vs SPY) |
| Jul 20, 2026 | Insider sale | Sibold William John sold $1.4M | −3.3% (−3.1% vs SPY) | −1.7% (−1.1% vs SPY) | −5.3% (−9.2% vs SPY) |
| Jun 17, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.2% (+0.1% vs SPY) | +2.8% (+3.4% vs SPY) | +6.9% (+6.5% vs SPY) |
| May 18, 2026 | Insider sale | Soergel David sold $435K | −0.3% (−0.2% vs SPY) | −1.2% (−2.1% vs SPY) | −4.4% (−5.9% vs SPY) |
| Apr 28, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.4% (+0.4% vs SPY) | −2.8% (−4.5% vs SPY) | −0.1% (−6.0% vs SPY) |
| Jan 30, 2026 | 8-K | Material definitive agreement | +0.1% (−0.4% vs SPY) | −2.4% (−2.2% vs SPY) | −13.9% (−12.2% vs SPY) |
| Dec 11, 2025 | 8-K | Directors and officers: departures, appointments, pay | 0.0% (+1.1% vs SPY) | −4.8% (−3.0% vs SPY) | −14.6% (−15.5% vs SPY) |
Insiders’ record here
In the year on the chart, Madrigal Pharmaceuticals' insiders reported 2 open-market buys ($25.2M) and 3 sales ($2.1M). Of the 2 old enough to score, 2 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −3.5%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Madrigal Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.